Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

41. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis

Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis 21778259 2012 02 08 2012 04 03 2016 11 25 1931-3543 141 2 2012 Feb Chest Chest Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. 461-8 10.1378/chest.11-0180 The aim of this study is to evaluate the efficacy and safety of medium-dose formoterol-budesonide combined inhaled treatment in a single inhaler compared with high-dose budesonide treatment in patients (...) with non-cystic fibrosis (non-CF) bronchiectasis. This is a 12-month randomized, double-blind, parallel-groups clinical trial, to run in 40 patients with non-CF bronchiectasis diagnosed by high-resolution CT scan of the chest, receiving formoterol-budesonide combined treatment (18/640 μg daily) or budesonide treatment (1,600 μg daily). Variables concerning clinical condition, health-related quality of life (HRQL), lung function, β(2)-adrenergic agonist use, potentially pathogenic microorganism (PPM

EvidenceUpdates2012

42. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study

Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study 22892337 2012 10 24 2013 01 14 2013 11 21 1528-0012 143 5 2012 Nov Gastroenterology Gastroenterology Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. 1218-26.e1-2 10.1053/j.gastro.2012.08.003 S0016-5085(12)01186-9 Budesonide (...) is a corticosteroid with minimal systemic corticosteroid activity due to first-pass hepatic metabolism. Budesonide MMX® is a once-daily oral formulation of budesonide that extends budesonide release throughout the colon using multi-matrix system (MMX) technology. We performed a randomized, double-blind, double-dummy, placebo-controlled trial to evaluate the efficacy of budesonide MMX for induction of remission in 509 patients with active, mild to moderate ulcerative colitis (UC). Patients were randomly assigned

EvidenceUpdates2012

43. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn`s disease

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn`s disease 21070781 2011 01 31 2011 03 28 2013 11 21 1528-0012 140 2 2011 Feb Gastroenterology Gastroenterology Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. 425-434.e1; quiz e13-4 10.1053/j.gastro.2010.11.004 Comparative data on budesonide vs mesalamine for the treatment of mild-to-moderately active Crohn's (...) disease (CD) are sparse. We assessed the efficacy and safety of each therapy in patients with mildly to moderately active CD. We performed a randomized, double-blind, double-dummy, 8-week, multicenter study in which 309 patients with mildly to moderately active CD received pH-modified-release oral budesonide (9 mg/day once daily or 3 mg/day 3 times daily) or Eudragit-L-coated oral mesalamine (4.5 g/day). The primary efficacy variable, clinical remission (defined as Crohn's Disease Activity Index ≤150

EvidenceUpdates2011

44. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Halpin DM, Gray J, Edwards SJ (...) , Morais J, Singh D CRD summary The review of indirect comparisons concluded that budesonide/formoterol was associated with fewer pneumonia events than salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. The authors' conclusions seem reasonable but reporting limitations mean that cautious interpretation is warranted. Authors' objectives To compare the efficacy of budesonide/formoterol with salmeterol/fluticasone on the incidence of pneumonia adverse events, pneumonia serious

DARE.2011

45. Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis

Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Comparative efficacy of indacaterol 150mug (...) and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP CRD summary This review concluded that indacaterol was expected to have similar effects on health status and breathlessness to salmeterol/fluticasone and similar effects on health status to formoterol/budesonide. It was also expected to be at least as good as formoterol

DARE.2011

46. Daily or intermittent budesonide in preschool children with recurrent wheezing.

Daily or intermittent budesonide in preschool children with recurrent wheezing. 22111718 2011 11 24 2011 12 09 2016 12 15 1533-4406 365 21 2011 Nov 24 The New England journal of medicine N. Engl. J. Med. Daily or intermittent budesonide in preschool children with recurrent wheezing. 1990-2001 10.1056/NEJMoa1104647 Daily inhaled glucocorticoids are recommended for young children at risk for asthma exacerbations, as indicated by a positive value on the modified asthma predictive index (API (...) ) and an exacerbation in the preceding year, but concern remains about daily adherence and effects on growth. We compared daily therapy with intermittent therapy. We studied 278 children between the ages of 12 and 53 months who had positive values on the modified API, recurrent wheezing episodes, and at least one exacerbation in the previous year but a low degree of impairment. Children were randomly assigned to receive a budesonide inhalation suspension for 1 year as either an intermittent high-dose regimen (1 mg

NEJM2011 Full Text: Link to full Text with Trip Pro

47. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis

Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis 20682320 2010 11 01 2010 11 30 2010 11 01 1528-0012 139 5 2010 Nov Gastroenterology Gastroenterology Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. 1526-37, 1537.e1 10.1053/j.gastro.2010.07.048 Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus characterized by dense tissue eosinophilia; it is refractory (...) to proton pump inhibitor therapy. EoE affects all age groups but most frequently individuals between 20 and 50 years of age. Topical corticosteroids are effective in pediatric patients with EoE, but no controlled studies of corticosteroids have been reported in adult patients. We performed a randomized, double-blind, placebo-controlled trial to evaluate the effect of oral budesonide (1 mg twice daily for 15 days) in adolescent and adult patients with active EoE. Pretreatment and posttreatment disease activity

EvidenceUpdates2010

48. Oral budesonide for induction of remission in ulcerative colitis.

Oral budesonide for induction of remission in ulcerative colitis. BACKGROUND: Corticosteroids remain one of the most popular medication choices for the induction of remission in ulcerative colitis and Crohn's disease. While corticosteroids may improve symptoms, they do not always result in mucosal healing and have significant adverse effects. Steroids which act topically, with less systemic side-effects may be more desirable. Oral budesonide, a topically acting corticosteroid with extensive (...) first pass hepatic metabolism, is effective in Crohn's disease and in enema formulation for left-sided ulcerative colitis. Data are limited regarding the role of oral budesonide in ulcerative colitis. OBJECTIVES: To systematically review the safety and efficacy of oral budesonide for induction of remission in ulcerative colitis. SEARCH STRATEGY: Electronic searching of the MEDLINE and EMBASE databases was performed. Two authors independently reviewed all identified titles and abstracts. Full text

Cochrane2010

49. Meta-analysis: Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease

Meta-analysis: Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease Article Text Therapeutics Meta-analysis Use of inhaled budesonide for 1 year does not increase risk

Evidence-Based Medicine (Requires free registration)2010

50. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study

Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study 19303012 2009 06 08 2009 07 08 2009 10 06 1528-0012 136 7 2009 Jun Gastroenterology Gastroenterology Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. 2092-100 10.1053/j.gastro.2009.02.078 Budesonide is effective in treating collagenous colitis, but no treatment is established for lymphocytic colitis. We performed a randomized (...) , double-blind, placebo-controlled study to evaluate the effects of budesonide in patients with lymphocytic colitis. Forty-two patients (median age, 61 years) with lymphocytic colitis and chronic diarrhea were randomly assigned to groups that were given oral doses of budesonide (9 mg/d) or placebo for 6 weeks. Nonresponders at week 6 were given open-label budesonide (9 mg/d) for 6 additional weeks. A complete colonoscopy and histologic and quality-of-life analyses were performed at baseline and at week

EvidenceUpdates2009

51. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol 19368965 2009 05 04 2009 05 26 2015 11 19 1097-6825 123 5 2009 May The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. 1083-9, 1089.e1-7 10.1016/j.jaci.2009.02.034 Budesonide/formoterol maintenance and reliever therapy maintains asthma control and reduces (...) exacerbation frequency compared with higher fixed-dose combination regimens. Its effects on eosinophilic airway inflammation and structure are unknown. We sought to compare the effects of budesonide/formoterol 200/6 microg twice daily plus as-needed with budesonide/formoterol 800/12 microg twice daily on airway eosinophils and remodeling. This 52-week, parallel-group, randomized, double-blind study of 127 asthma patients who were symptomatic despite therapy compared (1) the change between induced sputum

EvidenceUpdates2009

53. Oral budesonide for maintenance of remission of Crohn`s disease: a pooled safety analysis

Oral budesonide for maintenance of remission of Crohn`s disease: a pooled safety analysis 19035972 2009 02 25 2009 07 31 2014 11 20 1365-2036 29 6 2009 Mar 15 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. 643-53 10.1111/j.1365-2036.2008.03891.x Budesonide exhibits similar efficacy to systemic glucocorticosteroids (GCSs) in Crohn's disease (CD), but with fewer adverse events (AEs). Aim (...) To evaluate budesonide's safety profile in CD patients, in particular, incidences of clinically important AEs known to be associated with systemic GCSs. Five 1-year, double-blind, placebo-controlled trials evaluating budesonide for mild-to-moderate CD were pooled for analysis. The highest incidence rates of AEs were gastrointestinal- and endocrine systems-related in both groups (budesonide 6 mg/day, n = 208; placebo, n = 209). Incidence rates were similar, except for higher incidence of endocrine

EvidenceUpdates2009

54. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial

Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial 18669576 2008 12 18 2009 01 16 2014 07 30 1468-3288 58 1 2009 Jan Gut Gut Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. 68-72 10.1136/gut.2008.156513 To evaluate the efficacy and safety of long-term budesonide therapy for the maintenance of clinical remission in patients with collagenous colitis. Randomised, placebo-controlled (...) study with a 24-week, blinded follow-up period without any treatment. Three gastroenterology clinics in Denmark. Forty-two patients with histologically confirmed collagenous colitis and diarrhoea (more than three stools/day). Patients in clinical remission after 6 weeks' open-label therapy with oral budesonide (Entocort CIR capsules, 9 mg/day) received 24 weeks' double-blind maintenance therapy with budesonide 6 mg/day or placebo. Thereafter, patients entered the 24-week, blinded follow-up period

EvidenceUpdates2009

55. Budesonide for maintenance of remission in Crohn's disease.

Budesonide for maintenance of remission in Crohn's disease. BACKGROUND: Corticosteroids have been shown to be effective for induction, but not maintenance of remission in Crohn's disease. However, significant concerns exist regarding their risk for adverse events, particularly when used for long treatment courses. Budesonide is a glucocorticoid with limited systemic bioavailability due to extensive first-pass hepatic metabolism. Budesonide has been shown to be effective for induction (...) of remission in Crohn's disease. OBJECTIVES: To evaluate the efficacy and safety of oral budesonide for maintenance of remission in Crohn's disease. SEARCH STRATEGY: The following electronic databases were searched: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane IBD/FBD Group Specialised Trial Register, and ClinicalTrials.gov. Reference lists of articles, as well as conference proceedings were manually searched. Study authors, study sponsors and pharmaceutical companies

Cochrane2009

56. Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation

Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation Article Text Therapeutics Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation Statistics

Evidence-Based Medicine (Requires free registration)2009

57. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Sin D D, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, Calverley P M, Rennard S I CRD summary The review assessed the effects of inhaled budesonide on the risk of pneumonia in patients with chronic obstructive pulmonary disorder. The authors (...) concluded that budesonide treatment did not increase the risk of pneumonia and was safe. The small number of events in the analyses, coupled with limitations in review methodology, means the authors' conclusions should be interpreted with caution. Authors' objectives To assess the effects of inhaled budesonide on the risk of pneumonia in patients with chronic obstructive pulmonary disorder. Searching MEDLINE, EMBASE and an internal AstraZeneca database (Planet) were searched with no language or date

DARE.2009

58. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients 18455221 2008 06 09 2008 07 01 2015 11 19 1097-6825 121 6 2008 Jun The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma (...) patients. 1407-14, 1414.e1-6 10.1016/j.jaci.2008.03.019 The adjustable-dose budesonide/formoterol dry powder inhaler (DPI) has demonstrated similar or greater asthma control with less inhaled corticosteroid compared with the fixed-dose budesonide/formoterol DPI. We sought to evaluate the efficacy, tolerability, and resource use of maintenance therapy with the adjustable-dose budesonide/formoterol pressurized metered-dose inhaler versus the fixed-dose budesonide/formoterol pressurized metered

EvidenceUpdates2008

59. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.

Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. BACKGROUND: Combination therapies are frequently recommended as maintenance therapy for people with asthma, whose disease is not adequately controlled with inhaled steroids. Fluticasone/salmeterol (FP/SAL) and budesonide/formoterol (BUD/F) have been assessed against their respective monocomponents, but there is a need to compare these two therapies on a head (...) -to-head basis. OBJECTIVES: To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function. SEARCH STRATEGY: We searched the Cochrane Airways Group register of trials with prespecified terms. We performed additional hand searching of manufacturers' web sites and online trial registries. Searches are current to May 2008. SELECTION CRITERIA: Randomised studies comparing fixed dose FP/SAL and BUD/F were eligible, for a minimum

Cochrane2008

60. Budesonide for induction of remission in Crohn's disease.

Budesonide for induction of remission in Crohn's disease. BACKGROUND: Corticosteroids play a key role in the induction of remission in Crohn's disease. However, corticosteroids can cause significant adverse events. Budesonide is an alternate enteral glucocorticoid with limited systemic bioavailability. OBJECTIVES: The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission in Crohn's disease. SEARCH STRATEGY: The following electronic databases (...) were searched: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane IBD/FBD Group Specialised Trial Register, and ClinicalTrials.gov. Reference lists of articles, as well as conference proceedings were manually searched. Pharmaceutical companies were also contacted. SELECTION CRITERIA: Randomized controlled trials comparing budesonide to a control treatment were included. The study population included patients of any age with active Crohn's disease (CDAI > 150

Cochrane2008